Brett Linzey: Okay. Got it. And then just one last one on the margin outlook for this year. So 28% EBITDA margins, I was hoping you might be able to provide a little bit of context and dimension to the segment levels. FMT, specifically, I’m interested with that, softer, but how are you thinking about the, outlook for the segments around that 28%?
Abhi Khandelwal: Yeah, absolutely. I can do that for you. So as you saw in our guide for ’24 for the company is 28%. So if you think about HST, I think as we exit the year, you’re going to start to see our margins come closer to 30%, as the volumes flexes back up in the back half of the year. On the FMT side, you should expect slight bit of margin expansion on top of what you saw in 2023. And about the FSDP side, you should expect to see slight margin erosion due to the, completion of the big-box retailer refresh cycle, which puts some mix pressure on the margin line But again, HST you should see expansion, FMT slight bit of expansion and FSD a little bit of contraction, tied to dispensing.
Brett Linzey: Got it. Very helpful. Thank you.
Operator: Thank you. Our next question is from the line of Jeff Sprague with Vertical Research Partners. Please proceed with your questions.
Jeff Sprague: Thank you good morning everyone. A lot covered here, so maybe I’ll zoom out and Eric, maybe just a little bit longer-term perspective here. Some talk about, being positioned for the recovery and the like I just wonder your confidence level or your view on sort of normalized organic growth for the company, right? We’ve come through this tumultuous three years, but looking at it through the lens of kind of, your pre-COVID growth rate 2011 to 2019 was 3% or 4% organic, on average, it sounds like from Abhi’s comment, maybe there’s another point of price in the future relative what you have. But what is your confidence level that, maybe putting aside kind of a snapback here in 2025 that you’re at a higher level of organic growth going forward on a normalized basis?
Eric Ashleman: Yeah. Well, I appreciate the question and that’s absolutely where we’re heading. And so think of this as two levers primarily that we’re moving. One is just the nature of the portfolio of IDEX. So, we’ve been more aggressive towards capital deployment. Everything we’re bringing into IDEX today is inherently in faster-growing markets than, let’s say, more of the industrial core that we see, most notably in FMT. So, the comparative basis that’s tuning. We haven’t done a lot of pruning on the other side, it’s fairly modest. But to the extent we’re doing it, that’s actually moving that portfolio average up as well. And then, if with reasonable market support sort of absent massive swings of either way, as you suggested, I think we’ve long been targeting 200 basis points to 300 basis points of outperformance and everything we’re working on today is moving that towards the upper bound of that run-out.
So if you think of a world that let’s say would start to dial itself in more from a fundamental perspective towards something in the 2% to 3% range and sort of natural entitlement. And maybe that’s lifting from there because of the work that we’re doing, as I mentioned, and then out performance above it, it has us, moving into a space where we’re targeting mid-single-digit growth for IDEX. On an organic basis. With then obviously some, fundamental capital deployment on top of it, which would then extend the overall organic rate of the company. It’s absolutely the area of focus, has been for a while and we’re really, we’re excited about potentially taking out some of the forces that have been swinging up-and-down and sideways making that hard to see.
Jeff Sprague: And where do you stand on the view of price, right? You have more than normal still in 2024. There is some argument out there that industrial companies have, developed more price muscle coming through this period. Do you think, there’s kind of durable stickiness in the 2% range or do we sort of head back to something more like one over time?
Abhi Khandelwal: Well, look, first of all. I think to your point, where the world is we’re not back to the inflation levels that we were at, pre-pandemic. I mean even if you look at the near-term view it’s still at what 2.5%, 3%. So are we going to hang on to where we are today? No. Does that mean we’re going to, go back to where they used to be back in the historical levels? No, it’s going to be somewhere in the middle. But looking at 2024, we feel pretty good about our position and where we are from a price cost standpoint.
Eric Ashleman: And, I would say, here, I think this is a point of absolute point of competitive advantage for us, where price capture, we’ve always been in the price capture game. And we’ve done that because of our positioning and our innovation with great customers. Period. So, yes, we’ve come through a phase here where kind of everybody got price, because you had to. But, I think as the world normalizes here as Abhi says we’ll probably land a little north of where we’ve been, as long as the underlying, core inflation stays a little harder too. So we’ll maintain the spread that you’d expect. But I’m really proud and I think we will be noticed to be noticeably differentiated because of this core capability that we have to differentiate in sticky markets with risk-averse customers that reward us when we do our job well.
Jeff Sprague: Thanks. And just one other quick one. What percent of your total Life Sciences and Analytical is in China at this point?
Eric Ashleman: I mean, we don’t have a lot of direct business there, we’re kind of following customers. So it’s closer– a better ratio would be what percentage of their business is in China, which is– I mean it’s a fraction. It’s less than 20% plus or minus depending on the sector that we’re involved with. But again that’s– it’s kind of an indirect vectoring for us there. We don’t have a lot of feet on the ground there in a direct way.
Jeff Sprague: Got it. Thank you very much.
Operator: Our next question is from the line of Andrew Buscaglia with BNP. Please proceed with your question.
Andrew Buscaglia: Hey. Good morning, guys.
Abhi Khandelwal: Hey, Andrew.
Andrew Buscaglia: Just wanted to — on Slide 10, you gave a great breakdown of kind of where you’re thinking things shake out, where they’re going by end-market. I’m wondering HST, margins really kind of struggled towards the end of the year there. That Life Sciences and Analytical Instrumentation piece, how do we think about it from a mix standpoint because you mentioned mix a few times, I imagine if that were to come back this year that could be a nice bonus for your margins.
Abhi Khandelwal: Yeah. Just so I make myself clear. The mix that we were talking about was the mix of the dispensing business causing pressure in 2024 since the refresh cycle with the big-box retailers were over. But to go back to your question, if I think about the Life Sciences business and think about volumes coming back, I think as Eric mentioned just where we are positioned on our cost structure as the business has come back and we still see a little help from volume, you should see our margins expand in our HST segment throughout the year.
Andrew Buscaglia: Okay. In FMT, I thought that was surprising the growth you saw this quarter. How much is attributed to really like some of the government stimulus you’re seeing? And is that where some of your confidence is coming in ’24?
Eric Ashleman: I mean, that’s out there to some extent, it’s probably most directly linked to spaces like water within it. But that’s a small part of the overall segment. It’s an indirect relationship for us. So to the extent that is one of the elements that’s out there as a backstop, providing some confidence. Yes, it of course correlates. I would say more generally, for me this is it’s just a healthier view from a number of folks that think it’s time to be confident, lean into their markets, stop reaping inventory out of the system and kind of get to work. Again, just to make sure everybody can 3D think this through. So they’re building a lot of roads out there. I’ll use that as an example, or if they’re starting to fix them with abandon.
